Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG versus APIDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG versus APIDRA.
ADMELOG vs APIDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
Insulin glulisine is a rapid-acting insulin analog that lowers blood glucose by binding to and activating insulin receptors on cells, facilitating glucose uptake into muscle and adipose tissue, and inhibiting hepatic glucose production.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
Subcutaneous injection 0.2-0.4 units/kg once daily or divided twice daily, or as part of basal-bolus regimen with 50-70% of total daily insulin as prandial insulin given within 15 minutes before or within 20 minutes after starting a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control.
Terminal elimination half-life is approximately 30 minutes. This short half-life allows for flexible dosing and rapid clearance, but necessitates multiple daily injections or continuous subcutaneous insulin infusion.
Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys.
Primarily renal; ~60% of a dose is excreted as metabolites and unchanged drug in urine. Fecal elimination is minimal (<10%).
Category C
Category C
Insulin
Insulin